NHS Blood and Transplant Gene Therapy Hub
The NHSBT Gene Therapy Hub is part of the Clinical Biotechnology Centre (CBC). The CBC has been manufacturing GMP-grade DNA plasmids for over 20 years, and brings their wealth of expertise and experience transferring manufacturing processes to GMP compliance to the Innovation Hubs network. The NHSBT Gene Therapy Hub is hosted within a purpose built 1,000m2 facility for the production of gene therapies under GMP. The facility was funded jointly by NHSBT and the Department of Health and Social Care and is based at the NHSBT Filton Blood Centre (Bristol).
The Hub supports both early phase academic-led and commercial gene therapy trials, and facilitates the provision of cost-effective viral vectors and plasmid DNA to stimulate the UK’s gene therapy sector.
The CBC is led by Dr Jon Smythe and Dr Paul Lloyd-Evans, and provides viral vector manufacturing, training and support services for academic-led groups seeking Adeno Associated Viral (AAV), Lentiviral (LV) vectors and plasmid DNA at GMP and research-grade qualities.
NHSBT also supports academic-led teams in the translation of their research to the clinic and works with the other Hubs to develop, optimise and deliver a comprehensive training package. CBC is committed to generating a highly skilled workforce, serving both the academic and commercial gene therapy communities.
The CBC operates as part of the Cellular and Molecular Therapies (CMT) function within NHSBT. Other services provided by CMT include the development and manufacture of advanced cell therapies under GMP.
To find out more
- Click here to visit our NHSBT website
- Follow us on LinkedIn & Twitter
- Director: Dr Jon Smythe
- Co-Director: Dr Paul Lloyd-Evans
- Viral Vector Hub Manager: Dr Sujith Sebastian
- Project Manager: Charlotte McHugh
- Business Development Manager, Clinical Biotechnology Centre: Hollie Yaxley
- Head of Business Development, Cellular & Molecular Therapies: Teresina Pinnington
Bristol NHSBT Hub Timeline
First plasmid released
IHfGT project launch
Tech transfer of AAV platform complete
Scale-up to 50L complete
First validation studies commence
First GMP vector manufactured
New training courses available
Transition to self-sustaining Hub